Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : and the Elton John AIDS Foundation Launch RADIAN Initiative to Address HIV in Eastern Europe and Central Asia (EECA)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2019 | 07:32am EDT

-- Initiative to Provide Support to Local Organizations Working to Positively Impact the Lives of People Affected by and at Risk of HIV --

Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation today announced the launch of the ground-breaking RADIAN initiative at the Fast-Track Cities 2019 conference in London. RADIAN seeks to meaningfully address new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia (EECA). RADIAN builds on the existing collaboration between the Foundation and Gilead in the EECA Key Populations (EECAKP) fund, leveraging both organizations’ greater understanding of the region’s needs to drive forward bold and meaningful action to address specific challenges.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190909005498/en/

“Every day, more than 400 people in EECA become infected with HIV and 100 die from AIDS,” said Sir Elton John, Founder, Elton John AIDS Foundation. “My Foundation’s work in establishing the Eastern Europe and Central Asia Key Populations (EECAKP) fund with Gilead and others a couple of years ago forcefully underscored for us the need to drastically expand our efforts in the region. So, I’m delighted that the Foundation is once again working with Gilead through RADIAN to provide much-needed support and funding to reverse trends and reach some of the world’s most vulnerable people. Together, we can create change, save lives and ensure no one is left behind in the fight to end the epidemic.”

Addressing the epidemic in EECA is imperative to the global effort to eliminate HIV/AIDS. According to UNAIDS, while rates of new HIV infections and deaths from AIDS-related illnesses are now decreasing globally, EECA is one of the few regions where HIV is on the rise and deaths from AIDS have increased by approximately 300 percent in the last 20 years.

“Gilead and the Foundation share a vision to end the HIV epidemic. Through RADIAN, we aim to reach marginalized populations in the EECA region and work with local organizations to address some of the challenges they face,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “RADIAN will help to provide the funding and support for the HIV response that have historically been lacking in the region. There are more than one million people living with HIV in EECA who need access to appropriate care. This needs to be urgently addressed through education, community empowerment and novel partnerships such as this.”

The RADIAN initiative is comprised of two key elements, the RADIAN “Model Cities” program and the RADIAN “Unmet Need” fund. By adapting a dual-track program, RADIAN can direct resources to communities in need that are immediately ready to scale interventions through targeted funding, while simultaneously building capacity in others. HIV has high prevalence in communities that often face stigma and have limited access to care. By partnering with local organizations, RADIAN will leverage on-the-ground insights and share the best practices that are needed to make meaningful progress.

The first RADIAN Model City will be Almaty, Kazakhstan. Almaty faces a disproportionately heavy burden of HIV. There are approximately 7,400 people living with HIV in Almaty, and the city has an HIV prevalence that is almost twice the national average. RADIAN will support Almaty in achieving improved HIV outcomes by addressing stigma, strengthening healthcare infrastructure and care models and increasing access to innovation. Additional Model Cities will be announced in 2020.

“We are happy that Kazakhstan will be part of the RADIAN initiative,” said Dr. Bauyrzhan Baiserkin, Director of the Kazakh Scientific Center of Dermatology and Infectious Diseases, based in Almaty. “We have ambitions to reach those that live with or are at risk of HIV to ensure as many of them as possible can get tested and treated so they can live healthy lives. We welcome this support and commitment from the RADIAN initiative to help Kazakhstan continue our progress and ultimately achieve our targets.”

In order to support the rest of the EECA region beyond the selected Model Cities, RADIAN will also implement the Unmet Need fund, to support impactful initiatives in other parts of EECA. Grants will be available for local and regional organizations in EECA who share RADIAN’s vision to address new HIV infections and deaths from AIDS-related illnesses. The Request for Proposals will open in mid-October 2019.

Across both elements, RADIAN aims to contribute measurable changes in HIV incidence, linkage to care and treatment coverage and prevention, to meaningfully address new HIV infections and AIDS-related deaths in EECA. Best practices and learnings from the local implementation of RADIAN over the next five years will be used as a blueprint toward helping change the trajectory of HIV across the region.

About RADIAN

RADIAN is a ground-breaking initiative between the Elton John AIDS Foundation and Gilead Sciences. It aims to meaningfully address new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia (EECA), where deaths from AIDS have increased by around 300 percent in the last 20 years.

The Elton John AIDS Foundation and Gilead have an established presence in EECA and extensive experience working effectively with key stakeholders. Through a focused investment of up to $25 million, as well as provision of resources on the ground, RADIAN is a natural evolution of this initiative, leveraging a deep understanding of the EECA community to drive forward the shared ambition to end the HIV epidemic.

Both organizations, as well as potential additional partners in the future, will work together to ensure no one is left behind in the global effort to eliminate HIV/AIDS. Join us in addressing new HIV infections and deaths from AIDS-related illnesses in EECA: www.radianHIV.org.

About the Elton John AIDS Foundation

The Elton John AIDS Foundation is one of the foremost independent AIDS charities in the world. At the Foundation, we believe AIDS can be beaten. We act on that belief by raising funds for evidence-based frontline programs and policies and speaking out with honesty and compassion about the realities of people’s lives. Sir Elton John created the Foundation in 1992. Since then, through hard work and with the help of our network of kind and generous friends and supporters, the Foundation has raised more than $450 million globally to combat stigma, prevent infections, provide treatment and services, and motivate governments to end AIDS. Join us in speaking out, taking action, and continuing the fight against this worldwide pandemic so that no one is left behind.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it is estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

For more information, please visit www.ejaf.org, follow the Foundation on Twitter (@ejaf), Facebook @eltonjohnaidsfoundation and Instagram (@ejaf).

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
10:25aGRAPHIC - TAKE FIVE : Super Saturday, Super Mario
RE
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15GILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
AQ
10/15GILEAD SCIENCES : Names Andrew Dickinson Chief Financial Officer
DJ
10/15GILEAD SCIENCES : Appoints Andrew Dickinson as Chief Financial Officer
BU
10/10GILEAD SCIENCES : Galapagos See Efficacy in Advanced Rheumatoid Arthritis Study
DJ
10/10GILEAD SCIENCES : to Release Third Quarter 2019 Financial Results on Thursday, O..
BU
10/08GILEAD SCIENCES : Submits New Drug Application for Filgotinib for the Treatment ..
BU
10/07Gilead Sciences Names Merdad Parsey Chief Medical Officer
DJ
10/07GILEAD SCIENCES : Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
BU
More news
Financials (USD)
Sales 2019 22 346 M
EBIT 2019 11 670 M
Net income 2019 4 272 M
Finance 2019 649 M
Yield 2019 3,86%
P/E ratio 2019 17,8x
P/E ratio 2020 11,4x
EV / Sales2019 3,67x
EV / Sales2020 3,62x
Capitalization 82 611 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 79,88  $
Last Close Price 65,23  $
Spread / Highest target 45,6%
Spread / Average Target 22,5%
Spread / Lowest Target -8,02%
EPS Revisions
Managers
NameTitle
Daniel O'Day Chairman & Chief Executive Officer
Robin L. Washington CFO, Chief Accounting Officer & Executive VP
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
John Francis Cogan Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES4.28%82 611
VERTEX PHARMACEUTICALS6.26%45 680
REGENERON PHARMACEUTICALS-19.26%32 998
WUXI APPTEC CO., LTD.68.13%20 570
GENMAB32.08%13 649
NEUROCRINE BIOSCIENCES, INC.35.63%8 869